Check effectiveness of new vaccine against ebola

Untitled
The rVSV-ZEBOV vaccine was administered 5.837 people. | Photo: EFE

The World Health Organization (WHO) announced that the experimental vaccine against ebola showed have up to 100 percent of efficiency during a rehearsal on a large scale that it took place in Guinea.
Vaccine developed in Canada was developed by the company Merck, Sharpe & Dohme and administered through 2015 to 5.837 people, of which none contracted ebola.
On the contrary, 23 cases of the disease were recorded in a control group that was not subjected to vaccination.
The trial was conducted in a coastal area of the so-called lower Guinea, an area where still detected some spread of ebola when he began the study.
> WHO said the end of the ebola epidemic in West Africa the virus, highly lethal, it was detected for the first time in Sudan and Zaire in 1976, is transmitted by blood, tissue or organic liquids of infected people, but also cases of infection have been recorded through contact with sick animals or human corpses.
The deadly power of the ebola virus is highly variable. Of 50 percent of those infected reported in the recent African outbreak, only 10 percent survived the infection.